-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
FSD Pharma Inc. (NASDAQ:HUGE) Short Interest Up 15.9% in August
FSD Pharma Inc. (NASDAQ:HUGE) Short Interest Up 15.9% in August
FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 385,800 shares, a growth of 15.9% from the August 15th total of 332,900 shares. Approximately 2.2% of the shares of the stock are sold short. Based on an average daily volume of 60,600 shares, the days-to-cover ratio is currently 6.4 days.
FSD Pharma Stock Up 1.3 %
Shares of HUGE stock traded up $0.01 during trading on Monday, hitting $0.90. 58,545 shares of the stock traded hands, compared to its average volume of 108,672. The firm's fifty day moving average price is $0.93 and its 200-day moving average price is $0.90. FSD Pharma has a 52-week low of $0.69 and a 52-week high of $1.70.
Get FSD Pharma alerts:FSD Pharma (NASDAQ:HUGE – Get Rating) last released its quarterly earnings results on Friday, August 12th. The company reported ($0.21) EPS for the quarter.
Institutional Trading of FSD Pharma
A hedge fund recently bought a new stake in FSD Pharma stock. AdvisorShares Investments LLC bought a new stake in FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 170,431 shares of the company's stock, valued at approximately $148,000. AdvisorShares Investments LLC owned about 0.42% of FSD Pharma as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.26% of the company's stock.About FSD Pharma
(Get Rating)
FSD Pharma Inc, through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Further Reading
- Get a free copy of the StockNews.com research report on FSD Pharma (HUGE)
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 385,800 shares, a growth of 15.9% from the August 15th total of 332,900 shares. Approximately 2.2% of the shares of the stock are sold short. Based on an average daily volume of 60,600 shares, the days-to-cover ratio is currently 6.4 days.
納斯達克(FSD Pharma Inc.)是空頭股數8月份大幅增長的目標。截至8月31日，空頭股數共有38.58萬股，較8月15日的33.29萬股增長15.9%。大約2.2%的股票被賣空。以日均成交量60,600股計算，目前天數與回補比率為6.4天。
FSD Pharma Stock Up 1.3 %
消防處醫藥股上升1.3%
Shares of HUGE stock traded up $0.01 during trading on Monday, hitting $0.90. 58,545 shares of the stock traded hands, compared to its average volume of 108,672. The firm's fifty day moving average price is $0.93 and its 200-day moving average price is $0.90. FSD Pharma has a 52-week low of $0.69 and a 52-week high of $1.70.
在週一的交易中，巨型股票的股價上漲了0.01美元，達到0.90美元。該股有58,545股易手，而其平均成交量為108,672股。該公司的50日移動均線價格為0.93美元，200日移動均線價格為0.90美元。FSD Pharma的52周低點為0.69美元，52周高點為1.70美元。
FSD Pharma (NASDAQ:HUGE – Get Rating) last released its quarterly earnings results on Friday, August 12th. The company reported ($0.21) EPS for the quarter.
FSD Pharma(納斯達克：巨無霸評級)最近一次發佈季度收益報告是在8月12日(星期五)。該公司公佈了該季度每股收益(0.21美元)。
Institutional Trading of FSD Pharma
FSD Pharma的機構交易
About FSD Pharma
關於消防處藥業
(Get Rating)
(獲取評級)
FSD Pharma Inc, through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
FSD Pharma Inc.通過其子公司作為一家制藥研發公司運營。它的主要候選藥物包括正在進行治療新冠肺炎疾病的第二階段臨牀試驗的FSD-201。該公司還專注於Lucid-Topch，一種被發現用於潛在治療抑鬱症等神經精神疾病的精神活性分子；以及Lucid-MS，一種獲得專利的新化學實體，被證明在臨牀前模型中可以防止和逆轉髓鞘降解，這是多發性硬化症的潛在機制。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on FSD Pharma (HUGE)
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
- 免費獲取StockNews.com關於FSD Pharma的研究報告(Heavy)
- 仍然愛着它：投資者繼續光顧麥當勞
- 聯邦快遞剛剛提供了一個買入機會嗎？
- 自動區重新進入拉力賽模式，新高在望
- Upwork股價跌入便宜貨領域
- 克羅格百貨是你的一站式消費者史泰博股票
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《消防局醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對FSD Pharma和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧